دورة المؤشرنت للتحليل الفني
50 دينار كويتي
يبيله Gtcb
- بادئ الموضوع abo-fahad
- تاريخ البدء
abo-fahad
عضو نشط
- التسجيل
- 3 مايو 2006
- المشاركات
- 243
ونبي احد يفيدنى من هذا الخبر
GTC Biotherapeutics to Webcast Annual Meeting on May 24, 2006
FRAMINGHAM, Mass.--(BUSINESS WIRE)--May 17, 2006--GTC Biotherapeutics, Inc. ("GTC") (Nasdaq: GTCB) will webcast its 2006 Annual Meeting of Stockholders on May 24, 2006 starting at approximately 2:00 p.m. Eastern Time. The annual meeting is to be held at the Forefront Center for Meetings & Conferences in Waltham, Massachusetts. GTC expects to conduct the formal business portion of the meeting followed by a presentation to its stockholders.
To access the 2006 Annual Meeting live via the Internet, please log onto www.gtc-bio.com approximately 15 minutes before the start of the meeting to allow for any software downloads that may be necessary. Following the webcast of the meeting, an archive will be available at the same address.
The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the meeting at www.earnings.com, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (www.streetevents.com), a password-protected event management site.
GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. GTC currently has five products in its internal pipeline. ATryn(R) is GTC's recombinant form of human antithrombin and is under development for both the U.S. and with LEO Pharma A/S for Europe, Canada and the Middle East. In addition to the ATryn(R) program, GTC has development programs for a recombinant human alpha-1 antitrypsin, a recombinant human albumin, a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors, and a malaria vaccine. GTC also enters into partnering arrangements, or external programs, in which its technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional recombinant production systems. One of GTC's external programs is in clinical trials with transgenically produced product. Additional information is available on the GTC web site, http://www.gtc-bio.com.
هل الخبر ايجابي
GTC Biotherapeutics to Webcast Annual Meeting on May 24, 2006
FRAMINGHAM, Mass.--(BUSINESS WIRE)--May 17, 2006--GTC Biotherapeutics, Inc. ("GTC") (Nasdaq: GTCB) will webcast its 2006 Annual Meeting of Stockholders on May 24, 2006 starting at approximately 2:00 p.m. Eastern Time. The annual meeting is to be held at the Forefront Center for Meetings & Conferences in Waltham, Massachusetts. GTC expects to conduct the formal business portion of the meeting followed by a presentation to its stockholders.
To access the 2006 Annual Meeting live via the Internet, please log onto www.gtc-bio.com approximately 15 minutes before the start of the meeting to allow for any software downloads that may be necessary. Following the webcast of the meeting, an archive will be available at the same address.
The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the meeting at www.earnings.com, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (www.streetevents.com), a password-protected event management site.
GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. GTC currently has five products in its internal pipeline. ATryn(R) is GTC's recombinant form of human antithrombin and is under development for both the U.S. and with LEO Pharma A/S for Europe, Canada and the Middle East. In addition to the ATryn(R) program, GTC has development programs for a recombinant human alpha-1 antitrypsin, a recombinant human albumin, a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors, and a malaria vaccine. GTC also enters into partnering arrangements, or external programs, in which its technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional recombinant production systems. One of GTC's external programs is in clinical trials with transgenically produced product. Additional information is available on the GTC web site, http://www.gtc-bio.com.
هل الخبر ايجابي
بدون ارباح تذكرAbdulazeez
عضو نشط
السلام عليكم
الحال كله من بعضه بو فهد لما تبيع يصعد السهم
الله يرزقك ويرزقنا من خيره
الحال كله من بعضه بو فهد لما تبيع يصعد السهم
الله يرزقك ويرزقنا من خيره
دورة المؤشرنت للتحليل الفني
50 دينار كويتي